Drug intelligence / Profile preview

VS-200Cr

Development stage: Preclinical
Lead developer: Entrinsic Bioscience
Modality: Hydrogel Systems → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

VS-200Cr is a novel amino acid-based moisturizing cream developed by Entrinsic Bioscience Inc. It is currently being evaluated in a clinical study as part of the daily standard skincare regimen recommended during radiation therapy for breast cancer, with the primary goal of assessing its ability to improve skin redness associated with the treatment.

Beyond the preview

Go deeper on VS-200Cr.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-200Cr.

Explore the full profile